Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

Sanofi to Acquire Bioverativ for $11.6 Billion

Paul, Weiss is advising U.S. biopharmaceutical company Bioverativ Inc. in its proposed all-cash $11.6 billion acquisition by French pharmaceutical company Sanofi. Under the agreement announced January 22 and unanimously approved by the boards of both companies, Sanofi will acquire all outstanding shares of Bioverativ for $105 per share, a 64 percent premium to Bioverativ’s closing price on January 19. Waltham, Mass.-based Bioverativ is a leader in developing treatments for hemophilia and other rare blood disorders. The acquisition, Sanofi’s biggest in seven years and among the largest pharma deals in recent months, is expected to close in the spring, subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team includes corporate partners Scott Barshay, Jeff Marell and Thomas de la Bastide and counsel Kyle Seifried and Patricia Vaz de Almeida; tax partners Jeffrey Samuels and Scott Sontag and counsel Alyssa Wolpin; employee benefits partners Larry Witdorchic and Andy Gaines and counsel Jarrett Hoffman and Reuven Falik; antitrust partners Andrew Forman and Rick Rule and counsel Marta Kelly; and intellectual property partner Claudine Meredith-Goujon.

January 22, 2018

© 2018 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy